Fierce Pharma

MAY 31, 2024

With the FDA nod, Moderna's RSV vaccine becomes the company's second product to secure the FDA's backing.

FDA 284

FDA 284

MedCity News

MAY 31, 2024

Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their FDA nods last year. The post FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products appeared first on MedCity News.

FDA 124

FDA Marketing Biopharma Pharma 124

Fierce Pharma

MAY 31, 2024

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. | When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion.

Patients 257

Patients 257

MedCity News

MAY 31, 2024

Talkspace and Ovia Health by Labcorp introduced the Women’s Health Coalition for Digital Solutions. Other founding member companies of the coalition include Conceive, Evernow, FitOn, Nurx, Cove and Nutrium. The post Talkspace, Labcorp’s Ovia Health Launch Digital Women’s Health Coalition appeared first on MedCity News.

115

115

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

Sales

Fierce Pharma

MAY 31, 2024

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the drug has pulled off another feat by staring down the PD-1 king Keytrud | In the phase 3 HARMONi-2 trial, solo ivonescimab delivered a statistically significant and clinically meaningful improvement in progression-free survival over Keytruda monotherapy.

237

237

MedCity News

MAY 31, 2024

In this month’s episode, Senior Reporter Katie Adams explored some executive moves and layoffs that recently occurred in the healthcare world. She also interviewed Courtney Fortner, who stepped into the CEO role at population health company Navvis this month. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Courtney Fortner, CEO of Navvis appeared first on MedCity News.

Healthcare 113

Healthcare Healthcare 113

pharmaphorum

MAY 31, 2024

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data from two phase 3 trials.

111

111

Fierce Pharma

MAY 31, 2024

Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to show an overall survival benefit in a lung cancer study. | Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to prove an overall survival benefit in a lung cancer study. Japan's Asahi Kasei is moving to buy rare disease drugmaker Calliditas for about $1 billion.

Pharma 147

Pharma 147

pharmaphorum

MAY 31, 2024

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it down earlier this year.

FDA 111

FDA Marketing 111

Fierce Pharma

MAY 31, 2024

A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding | A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding along in Europe.

Medicine 130

Medicine FDA 130

Advertiser: ZoomInfo

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

Sales

pharmaphorum

MAY 31, 2024

Gilead's TROP2 ADC Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma.

110

110

MedCity News

MAY 31, 2024

What contributes to the stress and what BCBA employers can do to alleviate it The post Experiencing BCBA Burnout? Why It Happens and Tips to Combat It appeared first on MedCity News.

108

108

Pharmaceutical Technology

MAY 31, 2024

The US FDA has granted RMAT designation for BlueRock Therapeutics' cell therapy, bemdaneprocel (BRT-DA01), for Parkinson's disease.

FDA 105

FDA 105

MedCity News

MAY 31, 2024

How work friction takes shape, how it costs organizations, and how leaders can uncover long-term solutions The post Work Friction: The Sleeper Crisis Plaguing Healthcare Contact Centers appeared first on MedCity News.

Healthcare 107

Healthcare Healthcare 107

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

pharmaphorum

MAY 31, 2024

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive pulmonary disease (COPD). The CHMP’s positive opinion sets up Dupixent (dupilumab) to become the first biologic therapy for COPD in the EU and the first new treatment approach for the disease in over a decade.

FDA 105

FDA Medicine 105

Pharmaceutical Commerce

MAY 31, 2024

The latest news for pharma industry insiders.

Pharma 104

Pharma 104

MedCity News

MAY 31, 2024

Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal. The antibody drug conjugate had received accelerated FDA approval for this type of cancer in 2021. The post Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer appeared first on MedCity News.

FDA 102

FDA Biopharma Pharma 102

PharmaTimes

MAY 31, 2024

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines

92

92

Advertiser: ZoomInfo

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

Sales Strategy

MedCity News

MAY 31, 2024

Here is a selection of recent executive hires, promotions, retirements and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.

Healthcare 93

Healthcare Healthcare Pharma 93

European Pharmaceutical Review

MAY 31, 2024

The first treatment approved in the EU to target a genetic cause of amyotrophic lateral sclerosis (ALS), has been authorised by the European Commission (EC). QALSODY ® (tofersen) is indicated for adults with ALS associated with a mutation in the superoxide dismutase 1 gene ( SOD1 -ALS). The treatment is an antisense oligonucleotide (ASO) designed to bind to SOD1 mRNA to reduce SOD1 protein production, Biogen shared.

Pharmaceutical 91

Pharmaceutical Medicine Patients Marketing 91

PharmaTimes

MAY 31, 2024

The projects will focus on a range of research areas, including Down’s syndrome and ALS

Pharmaceutical 86

Pharmaceutical Medical 86

Healthcare Success

MAY 31, 2024

Marketing the importance of preventive healthcare services is challenging, costly, and often conflicts with consumer behavior. Despite these hurdles, the urgency to promote prevention has never been greater. Why? The growing number of people diagnosed with preventable chronic diseases each year is staggering (think cancer cases resulting from smoking and diabetes and heart disease cases resulting from obesity).

Healthcare 73

Healthcare Healthcare Marketing Media 73

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmaceutical Technology

MAY 31, 2024

The EC has approved Biogen's QALSODY to treat adults with amyotrophic lateral sclerosis (ALS) linked to SOD1-ALS mutation.

59

59

PharmExec

MAY 31, 2024

In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvoseltamab, Regeneron talks about the possibility of linvoseltamab becoming a frontline treatment for multiple myeloma (MM) as well as the company's VelociSuite technology.

52

52

Pharmaceutical Commerce

MAY 31, 2024

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

Pharma 52

Pharma 52

PharmExec

MAY 31, 2024

Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340 per share of common stock in cash.

52

52

Advertiser: ZoomInfo

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

Prospecting

Pharmaceutical Commerce

MAY 31, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Networking 52

Networking Distribution Biopharma Healthcare 52

PharmExec

MAY 31, 2024

Results of a Phase III trial indicated that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

52

52

Penrod

MAY 31, 2024

1. Personalize Collection Strategies Looking at your historical data can help you create a compelling collection plan for specific patients. Another invaluable tool is the data from a financial clearing house. It’ll help you identify the likelihood of a patient paying and those that might not. You can use this information to determine the best course of action, including decisions to send a patient’s account to a professional collection agency.

Patients 52

Patients Insurance Networking Medical 52

PharmaTech

MAY 31, 2024

Sterling is strengthening its development and manufacturing services for ADCs with a dedicated GMP suite at its Wisconsin facility.

Manufacturing 52

Manufacturing 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients